FY2026 Earnings Forecast for Adagene Issued By HC Wainwright

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) – Equities researchers at HC Wainwright lowered their FY2026 earnings per share (EPS) estimates for shares of Adagene in a research report issued on Monday, September 14th. HC Wainwright analyst A. He now expects that the company will post earnings of ($0.43) per share for the year, down from their prior forecast of ($0.37). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Adagene’s current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Adagene’s FY2027 earnings at ($0.42) EPS, FY2028 earnings at ($0.70) EPS, FY2029 earnings at ($1.07) EPS and FY2030 earnings at ($0.87) EPS.

ADAG has been the topic of a number of other reports. Guggenheim reaffirmed a “buy” rating and set a $10.00 price objective on shares of Adagene in a research note on Tuesday, July 14th. Chardan Capital began coverage on Adagene in a research note on Thursday, September 10th. They issued a “buy” rating and a $9.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adagene in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.67.

Adagene Stock Down 9.2%

Shares of NASDAQ ADAG opened at $2.97 on Wednesday. The company has a current ratio of 5.02, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01. Adagene has a one year low of $1.30 and a one year high of $4.85. The firm’s 50 day simple moving average is $3.71 and its two-hundred day simple moving average is $3.72.

Insider Activity at Adagene

In other news, CEO Peter Luo bought 22,966 shares of the stock in a transaction dated Tuesday, August 4th. The stock was bought at an average price of $3.65 per share, for a total transaction of $83,825.90. Following the purchase, the chief executive officer directly owned 67,966 shares in the company, valued at $248,075.90. This trade represents a 51.04% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders purchased 25,245 shares of company stock valued at $92,344. Company insiders own 21.20% of the company’s stock.

Institutional Investors Weigh In On Adagene

An institutional investor recently bought a new position in Adagene stock. Renaissance Technologies LLC purchased a new position in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 34,533 shares of the company’s stock, valued at approximately $135,000. Renaissance Technologies LLC owned approximately 0.07% of Adagene as of its most recent SEC filing. Institutional investors own 9.51% of the company’s stock.

Adagene Company Profile

Adagene Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines for cancer and other serious diseases. The company combines computational antibody-design capabilities with laboratory-based discovery and development platforms to create differentiated therapeutic candidates.

Adagene’s technology portfolio includes its SAFEbody platform, which is designed to mask antibody binding sites until the medicines reach the tumor microenvironment, potentially improving tumor selectivity and reducing activity in healthy tissue.